New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
10:26 EDTMDAS, HSY, DG, CS, BMO, NJR, MANU, FIATY, DLR, CRZBD, WOPEY, NGG, AWAY, EDPFY, DSW, CELG, PAGPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bank of Montreal (BMO) downgraded to Sector Perform from Outperform at RBC Capital... Celgene (CELG) downgraded to Neutral from Overweight at JPMorgan... Commerzbank (CRZBD) downgraded to Neutral from Outperform at Exane BNP Paribas... Credit Suisse (CS) downgraded to Neutral from Buy at BofA/Merrill... DSW (DSW) downgraded to Neutral from Positive at Susquehanna... Digital Realty (DLR) downgraded to Hold from Buy at Cantor... Dollar General (DG) downgraded at Sterne Agee... Energias de Portugal (EDPFY) downgraded to Sell from Neutral at Citigroup... Fiat (FIATY) downgraded to Underperform from Market Perform at Bernstein... Hershey (HSY) downgraded to Hold from Buy at Argus... HomeAway (AWAY) downgraded to Neutral from Overweight at JPMorgan... Manchester United (MANU) downgraded to Neutral from Overweight at JPMorgan... MedAssets (MDAS) downgraded to Neutral from Buy at Citigroup... National Grid (NGG) downgraded to Neutral from Outperform at Credit Suisse... New Jersey Resources (NJR) downgraded to Hold from Buy at Brean Capital... Plains GP Holdings (PAGP) downgraded to Equal Weight from Overweight at Stephens... Woodside Petroleum (WOPEY) downgraded to Market Perform from Outperform at Bernstei.
News For BMO;CELG;CRZBD;CS;DSW;DLR;DG;EDPFY;FIATY;HSY;AWAY;MANU;MDAS;NGG;NJR;PAGP;WOPEY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 30, 2015
07:03 EDTCELGJuno volatility low into announcing immunotherapy collaboration with Celgene
Subscribe for More Information
June 29, 2015
19:01 EDTCELGOn The Fly: After Hours Movers
HIGHER: Juno Therapeutics (JUNO), up 38.4% after announcing immunotherapy collaboration with Celgene (CELG)... Kite Pharma (KITE) and Lion Biotechnologies (LBIO) are up 8.7% and 5.7% respectively, following Juno's collaboration with Celgene. DOWN AFTER EARNINGS: CHC Group (HELI), down 8%... Apollo Education (APOL), down 6.2%. ALSO LOWER: EnteroMedics (ETRM), down 12.4% after filing to sell common stock and warrants... Celgene (CELG), down 1% after Juno announces immunotherapy collaboration.
18:09 EDTCELGJuno surges after Celgene collaboration, CAR-T peers follow
Subscribe for More Information
16:09 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Celgene (CELG) and Juno Therapeutics (JUNO) announced a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology and T Cell Receptor technologies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. For Juno-originated programs co-developed under the collaboration: Juno will be responsible for research and development in North America and will retain commercialization rights in those territories; Celgene will be responsible for development and commercialization in the rest of the world, and will pay Juno a royalty on sales in those territories; and Celgene has certain co-promotion options: Celgene will initially be eligible to select two programs, excluding CD19 and CD22, to be subject to a global profit sharing agreement under which the companies will share worldwide expenses and profits equally, except in China; and Additionally, subject to additional obligations, Celgene may select a third program. Juno will have the option to enter into a co-development and co-commercialization agreement on certain Celgene-originated development candidates that target T Cells. For any such Celgene-originated programs co-developed under the collaboration: The parties will share global costs and profits with 70% allocated to Celgene and 30% allocated to Juno; and Celgene will lead global development and commercialization, subject to a Juno co-promote option in the US and certain EU territories. Upon closing, Juno will receive an upfront payment of approximately $150M, and in addition Celgene will purchase 9,137,672 shares of Juno’s common stock at $93.00 per share. In conjunction with this stock purchase: Celgene will receive the right to nominate a member to Juno’s board of directors; During the 10-year term of the collaboration, Celgene will have the right to purchase additional equity in Juno during specified windows and at specified market premiums subject to satisfaction of certain conditions by each party including Juno opting in on select Celgene programs, such that, at a maximum, Celgene could own up to 30% of Juno’s common stock then outstanding; and Celgene has entered into a standstill agreement and agreed to certain lock-up provisions on its share ownership. This transaction has been approved by the boards of directors of both companies. Celgene and Juno currently expect to complete the transaction during the third quarter of 2015, subject to the expiration or termination of applicable waiting periods under all applicable antitrust laws and satisfaction of other usual and customary closing conditions.
16:08 EDTCELGJuno jumps 45% after announcing immunotherapy collaboration with Celgene
Subscribe for More Information
16:07 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Subscribe for More Information
06:47 EDTCSCredit Suisse, ING aiming to move some activities out of London, FT says
Subscribe for More Information
June 28, 2015
17:05 EDTCSBank regulator probes 'Isdafix' benchmark manipulation, FT says
Subscribe for More Information
13:42 EDTDLRDigital Realty sees significant uptick in analyst upgrades, Barron's says
Digital Realty has seen a 24% net uptick in Buy ratings on the stock over the past two weeks, and "investors would be wise to listen," Barron's contends in a 'Trader Extra' column, citing Fundstrat research. Barron's notes that the improved analyst sentiment is largely due to an expected increase in Q2 leasing activity as well as reports of a potential bid for TELX Group. Reference Link
June 26, 2015
12:00 EDTDSWFinish Line rises after Q1 results beat expectations
Subscribe for More Information
11:32 EDTCELGCelgene looks to protect itself from Kyle Bass patent challenges, WSJ says
Subscribe for More Information
June 25, 2015
08:01 EDTDGDollar General names John Garratt as interim CFO, effective July 1
Subscribe for More Information
June 24, 2015
07:30 EDTDLRUBS to hold a tour
Subscribe for More Information
07:18 EDTPAGPCredit Suisse to hold a conference
2015 MLP & Energy Logistics Conference is being held in New York on June 23-24 with webcasted company presentations to begin on June 24 at 8 am; not all company presentations may be webcasted. Webcast Link
June 23, 2015
08:56 EDTDLRCitigroup to hold a field trip
European Housing Field Trip travels throughout Europe visiting with various companies on June 23-26.
07:43 EDTDLRMitsubishi UFJ to hold a conference
Subscribe for More Information
06:53 EDTCSPSAV prepares for IPO that could raise roughly $300M, Bloomberg says
Subscribe for More Information
June 22, 2015
11:15 EDTMANUManchester United management to meet with Jefferies
Subscribe for More Information
07:13 EDTBMOUBS to hold a conference
Subscribe for More Information
June 21, 2015
19:38 EDTNGGNational Grid CEO Steve Holliday to step down, Sunday Times says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use